@phdthesis{oai:niigata-u.repo.nii.ac.jp:02000284,
 author = {Oshikane, Tomoya and 押金, 智哉},
 month = {2022-04-04, 2022-04-04},
 note = {We aimed to compare the outcomes of high-dose-rate brachytherapy (HDR-BT) boost and external beam radiation therapy (EBRT) alone for high-risk prostate cancer. This was a single-center, retrospective, and observational study. Consecutive patients who underwent initial radical treatment by HDR-BT boost or EBRT alone from June 2009 to May 2016 at the Niigata University Medical and Dental Hospital, Japan were included. A total of 96 patients underwent HDR-BT boost, and 61 underwent EBRT alone. The prescription dose of HDR-BT boost was set to 18 Gy/2 times/day with EBRT 39 Gy/13 fractions. The dose for EBRT alone was mostly 70 Gy/28 fractions. The high-risk group received >6 months of prior androgen deprivation therapy. Overall survival, biochemical-free survival, local control, and distant metastasis-free survival rates at 5 years were analyzed. The incidence of urological and gastrointestinal late adverse events of G2 and above was also summarized. In the National Comprehensive Cancer Network (NCCN) high-risk, HDR-BT boost had a significantly higher biochemical-free survival rate at 5 years (98.9% vs 90.7%, p = 0.04). Urethral strictures were more common in the HDR-BT boost group. We will continuously observe the progress of the study patients and determine the longer-term results., Journal of Radiation Research. 2021, 62(3), 525–532., 新大院博(医)第979号},
 school = {新潟大学, Niigata University},
 title = {A Comparative Study of High-dose-rate Brachytherapy Boost Combined with External Beam Radiation Therapy Versus External Beam Radiation Therapy Alone for High-risk Prostate Cancer},
 year = {}
}